A Phase I, Open-label Study to Evaluate the Pharmacokinetics of Tezepelumab in Children ≥ 5 to 11 Years of Age With Mild, Moderate, or Severe Asthma (TRAILHEAD)
Latest Information Update: 20 Feb 2025
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Acronyms TRAILHEAD
- Sponsors AstraZeneca
Most Recent Events
- 14 Oct 2022 Status changed from active, no longer recruiting to completed.
- 14 Jul 2022 Planned End Date changed from 22 Sep 2022 to 28 Sep 2022.
- 14 Jul 2022 Planned primary completion date changed from 22 Sep 2022 to 28 Sep 2022.